Latest news for  (OTC:SXERF) Stock

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) stock remained largely unchanged this week as investors digested NVIDIA Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42121215/nvidia-post-earnings-jitters-can-nvda-stock-regain-its-ai-fueled-momentum">third-quarter earnings report</a>.
Nvidia, AMD&#8217;s key competitor in high-performance GPUs and AI hardware, posted solid third-quarter results that beat analyst expectations. However, its guidance for the fourth quarter dampened enthusiasm, leaving some investors cautious about the short-term outlook.
What To Know: Analysts praised Nvidia's performance, noting strong AI demand and a robust product pipeline, particularly around its next-generation Blackwell architecture. 
Cantor Fitzgerald and Piper Sandler analysts emphasized that the Blackwell ramp is outpacing initial expectations, and demand continues to outstrip supply. Despite this, Nvidia's guidance for fourth quarter gross margins and revenue fell short of lofty investor expectations, triggering some profit-taking.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42135905/bitcoin-nears-100000-momentum-could-continue-well-beyond-the-milestone-experts-note">Bitcoin Nears $100,000, &#8216;Momentum Could Continue Well Beyond The Milestone,&#8217; Experts Note</a>
For AMD, the lack of significant movement in its stock price reflects the lingering uncertainty in the sector. While Nvidia solidifies its dominance in AI hardware, AMD has been making inroads with its MI300 chips, targeting similar data center and AI workloads. Investors appear to be awaiting clearer signs of market share gains or a breakout moment for AMD in the competitive AI space.
Nvidia's results serve as a bellwether for the broader semiconductor industry, and the mixed reactions highlight investor sensitivity to future growth prospects amidst a year of outsized gains for AI-related stocks. 
With AMD and Nvidia navigating a rapidly evolving landscape, all eyes remain on product launches and guidance updates in early 2025.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/11/42094649/nvidia-stock-historically-drops-in-december-after-q3-earnings">Nvidia Stock Historically Drops In December After Q3 Earnings</a>
<h2 class="wp-block-heading">How To Buy AMD Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Advanced Micro Devices&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMD has a 52-week high of $227.30 and a 52-week low of $116.37.

News

NVDA

What's Going On With AMD Stock?

WIIM

TMDX

TransMedics shares are trading lower after Needham downgraded the stock from Buy to Hold.

Hidetaka Miyazaki, the director of Elden Ring and president of FromSoftware, apologized to fans for the long wait for the Shadow of the Erdtree DLC while accepting the Best Game Expansion award during the <a href="https://www.benzinga.com/general/gaming">Golden Joystick Awards.</a> 
In a video message, Miyazaki expressed gratitude to fans for their support and teased that the studio is working on multiple new projects.ç
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/42068231/sony-in-talks-to-acquire-elden-ring-publisher-kadokawa-report">Sony In Talks To Acquire Elden Ring Publisher Kadokawa: Report</a>
&#8220;I must sincerely apologize for the lengthy wait of over two years since the release of the main game to deliver this DLC,&#8221; Miyazaki said. 
He called the award an "incredible honor" and thanked players for their patience and dedication. "Receiving such a prestigious reward brings me great relief, and I am deeply thankful to all the players who enjoyed and supported the main game and the DLC."
<h3 class="wp-block-heading">FromSoftware Has New Projects In Development</h3>
"We are currently working on various new projects, and I hope you will look forward to what we have in store next," Miyazaki said.
However, he didn't elaborate on what these might be, <a href="https://www.benzinga.com/general/entertainment/24/07/39579853/george-r-r-martin-fuels-rumors-about-elden-ring-movie-or-tv-show">leaving fans to speculate. </a>
In June, Miyazaki admitted that even his own team supports fans&#8217; calls for a PC port of Bloodborne. Speaking to PC Gamer, he jokingly said, &#8220;I know for a fact these guys want a Bloodborne PC port. If I say I want one, I&#8217;ll get in trouble as well. But it&#8217;s nothing I&#8217;m opposed to.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42121273/baldurs-gate-3-sees-more-players-in-2024-than-during-launch-year-heres-why">Baldur&#8217;s Gate 3 Sees More Players In 2024 Than During Launch Year: Here&#8217;s Why</a></li>
</ul>
Photo: Shutterstock

Gaming

General

Elden Ring Creator Hidetaka Miyazaki Teases 'Various New Projects' In Development

Carpenter Technology shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a price target of $200.

CROX

Crocs shares are trading higher after Needham initiated coverage on the stock with a Buy rating and announced a price target of $116.

Piper Sandler analyst Rob Owens maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Overweight and raises the price target from $100 to $130.

Price Target

Analyst Ratings

ESTC

Piper Sandler Maintains Overweight on Elastic, Raises Price Target to $130

PTGX

Protagonist Therapeutics shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

Piper Sandler analyst Kashy Harrison maintains Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) with a Neutral and lowers the price target from $8 to $4.5.

NOVA

Piper Sandler Maintains Neutral on Sunnova Energy Intl, Lowers Price Target to $4.5

Piper Sandler analyst Kashy Harrison maintains Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) with a Neutral and lowers the price target from $1.5 to $0.3.

STEM

Piper Sandler Maintains Neutral on Stem, Lowers Price Target to $0.3

KRRO

Korro Bio shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

KURA

Kura Oncology shares are trading higher. B of A Securities maintained a Buy rating on the stock.

NGVC

Natural Grocers shares are trading higher after the company reported better-than-expected Q4 financial results and announced a quarterly dividend increase from $0.10 to $0.12.

Piper Sandler analyst Kashy Harrison maintains Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) with a Overweight and lowers the price target from $10 to $8.

SHLS

Piper Sandler Maintains Overweight on Shoals Technologies Gr, Lowers Price Target to $8

Piper Sandler analyst Kashy Harrison maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Overweight and lowers the price target from $60 to $47.

Piper Sandler Maintains Overweight on NEXTracker, Lowers Price Target to $47

Shoals Technologies Group shares are trading higher. The company announced its CEO bought $101k worth of stock.

Piper Sandler analyst Kashy Harrison maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Overweight and raises the price target from $190 to $200.

GNRC

Piper Sandler Maintains Overweight on Generac Hldgs, Raises Price Target to $200

In the latest quarter, 8 analysts provided ratings for Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $110.88, a high estimate of $119.00, and a low estimate of $105.00. Surpassing the previous average price target of $108.88, the current average has increased by 1.84%.
<img src="https://www.benzinga.com/files/images/story/2024/1732291255_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Eastman Chemical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$119.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Eastman Chemical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Eastman Chemical's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Eastman Chemical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eastman Chemical analyst ratings.</a>
<h2>Get to Know Eastman Chemical Better</h2>
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
<h3>Eastman Chemical's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Eastman Chemical displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 8.69%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.31%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Eastman Chemical's ROA excels beyond industry benchmarks, reaching 1.2%. This signifies efficient management of assets and strong financial health.
Debt Management: Eastman Chemical's debt-to-equity ratio is below the industry average. With a ratio of 0.89, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Eastman Chemical: 8 Analysts Share Their Views

In the preceding three months, 6 analysts have released ratings for Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Janux Therapeutics, presenting an average target of $80.17, a high estimate of $100.00, and a low estimate of $63.00. This current average has decreased by 8.55% from the previous average price target of $87.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1732291248_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Janux Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey La Rosa</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$79.00</td>
<td>-</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$69.00</td>
<td>-</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Bradley Canino</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Janux Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Janux Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Janux Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Janux Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JANX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Janux Therapeutics analyst ratings.</a>
<h2>All You Need to Know About Janux Therapeutics</h2>
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
<h3>Janux Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Janux Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -82.56% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Janux Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -6391.57%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Janux Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.27%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Janux Therapeutics's ROA excels beyond industry benchmarks, reaching -4.05%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JANX

Evaluating Janux Therapeutics: Insights From 6 Financial Analysts

First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) has been analyzed by 21 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for First Solar, revealing an average target of $275.29, a high estimate of $343.00, and a low estimate of $210.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.57%. 
<img src="https://www.benzinga.com/files/images/story/2024/1732291241_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive First Solar is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$257.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$335.00</td>
<td>$368.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$279.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Chris Dendrinos</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$245.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Sean Morgan</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$278.00</td>
<td>$281.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$252.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$297.00</td>
<td>$329.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$269.00</td>
<td>$321.00</td>
</tr>
<tr>
<td>Sean Milligan</td>
<td>Janney Montgomery Scott</td>
<td>Announces</td>
<td>Buy</td>
<td>$260.00</td>
<td>-</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$254.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$280.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Philip Shen</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$280.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Dushyant Ailani</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$266.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$321.00</td>
<td>$343.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Julien Dumoulin-Smith</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$343.00</td>
<td>$320.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to First Solar. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of First Solar compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of First Solar's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into First Solar's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FSLR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on First Solar analyst ratings.</a>
<h2>Discovering First Solar: A Closer Look</h2>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
<h3>Understanding the Numbers: First Solar's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: First Solar's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 10.81%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 35.26%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.79%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.09.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

News

Latest news for (OTC:SXERF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga